Use of phosphate-binding agents is associated with a lower risk of mortality
about
Lanthanum carbonate: safety data after 10 yearsPhosphate binders in chronic kidney disease: a systematic review of recent data.A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum.Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patientsTip-toeing toward the finish line.Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?Con: Phosphate binders in chronic kidney diseasePhosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.Next-generation phosphate binders: focus on iron-based binders.Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease?The challenge of controlling phosphorus in chronic kidney disease.Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial.Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease.Advances in pharmacotherapy for hyperphosphatemia in renal disease.The role of phosphate in kidney disease.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease.Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study).Treating hyperphosphatemia - current and advancing drugs.Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No' at the moment, but stay tuned.Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients.All that glitters is not gold: A case of lanthanum carbonate aspirationSurvival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction?The role of calcium and non calcium-based phosphate binders in chronic kidney disease.
P2860
Q28079982-E465110B-EFF0-46EA-AAF3-C2969E6E5DE1Q31039292-2EBB42EB-AE56-4A00-B106-2C6190BCADC8Q33916132-D3C2AD5C-2475-4580-98B0-31CD578CA245Q34403555-E01B1EEC-4C9B-4E10-BD16-1FECE90C26DCQ34463433-805B33CD-06CA-47D7-8EF4-047792B075BAQ34865383-A51FC9D7-ADB4-45E9-8E82-59A908C54F7BQ35207839-480A7B01-9191-41AB-8C79-6B0CB739DE71Q36497902-EC329FA9-F1B7-477D-BD12-1BB1AFDFF494Q38202179-AF2F055C-3E3B-43EE-97B4-43B2410A6A45Q38213502-7D54EB99-8943-4986-AC28-C2FCE4BDF549Q38219038-2404A077-5F16-4901-8D8D-CE22D9DF49A5Q38223280-9A95CC7E-E9D9-4E03-A32A-E3617363B0B5Q38377286-AA958EFB-18CE-47FC-9AF1-8A12C41549B3Q38389206-9FA01B93-A31A-4C15-9099-AEAD86C0D560Q38435719-B4F2FB2C-F920-4D0D-A8CF-141DC064F235Q38567745-E2D1BB3C-2DC5-4BC0-BE87-DC51D6A832A0Q38587575-E1B07B6E-CB8A-432A-9055-7A8C53C1D72FQ38793054-232034F5-8880-4AF7-9605-2B81526F6C75Q38828902-C6F5876A-5897-4EF8-A6D4-32E22E6A0906Q38837072-5B597B0A-67A6-4BC4-9C63-930DE7E16D30Q38901641-1D37DEB7-D54A-46EA-91A0-2AADBB39C2C7Q38958363-EAD01874-53FE-4FBC-B378-31195BEAE55EQ39440902-E68262C3-6A1C-4F11-A5D8-34C059300B8EQ40226740-3106D76C-1361-4378-98B7-85031FA9020AQ40974681-C5DC36CD-E2E4-4AAB-BB38-9DD65567A818Q41038606-D4275661-2BDB-413D-B8B2-C1A0E7C8C9EDQ41661620-15830084-E01A-4890-98D2-12423BDA93E4Q42221191-40B7158F-DC1B-4F67-8AAC-7600E9612AB3Q44471363-C3BE51E8-859D-4EFA-BDC5-14E138DC86A0Q52674802-7CC5B644-380A-45FA-9FA7-348B8CC6AB25Q54081159-26408960-D05D-4A92-A670-0120F800812D
P2860
Use of phosphate-binding agents is associated with a lower risk of mortality
description
im November 2013 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 03 July 2013
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2013
@uk
name
Use of phosphate-binding agents is associated with a lower risk of mortality
@en
Use of phosphate-binding agents is associated with a lower risk of mortality
@nl
type
label
Use of phosphate-binding agents is associated with a lower risk of mortality
@en
Use of phosphate-binding agents is associated with a lower risk of mortality
@nl
prefLabel
Use of phosphate-binding agents is associated with a lower risk of mortality
@en
Use of phosphate-binding agents is associated with a lower risk of mortality
@nl
P2093
P50
P356
P1433
P1476
Use of phosphate-binding agents is associated with a lower risk of mortality
@en
P2093
Adrian Covic
Boleslaw Rutkowski
Christian Tielemans
David Goldsmith
Dierik Verbeelen
Dimitrios Memmos
Francesco Locatelli
Gérard London
José Emilio Sánchez
José L Gorriz
P2888
P304
P356
10.1038/KI.2013.185
P407
P50
P577
2013-07-03T00:00:00Z